Search clinical trials for: Lenvima

Total 140 results

Gustave Roussy, Cancer Campus, Grand Paris
Medical University of Vienna; University Hospital, Essen; Fondazione IRCCS Istituto... and other collaborators

Recruiting

CARE1 Pragmatic Clinical Trial (CARE1)

Metastatic Kidney Carcinoma | Metastatic Kidney Cancer

France
Chang Gung Memorial Hospital
Ministry of Health and Welfare, Taiwan

Recruiting

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

High Risk of Recurrence

Taiwan
University of Texas Southwestern Medical Center
Merck Sharp & Dohme LLC

Recruiting

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Cervical Cancer | Cervix Cancer

United States
Mian XI

Recruiting

Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401) (HSBRT2401)

Hepatocellular Carcinoma

China
Tongji Hospital

Not yet recruiting

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Hepatocellular Carcinoma

China
Peking University First Hospital
Merck Sharp & Dohme LLC

Not yet recruiting

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung Cancer

China
Tel Aviv Medical Center

Not yet recruiting

Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma

GBM
University Medical Center Groningen

Not yet recruiting

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE)

Renal Cell Carcinoma | Breast Carcinoma | Thyroid Carcinoma | Ovarian Carcinoma | Endometrium Carcinoma

Netherlands
National Cancer Center, Japan
Merck Sharp & Dohme LLC

Recruiting

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) (Artemis)

Untreated Advanced or Recurrent Thymic Carcinomas

Japan
Regina Elena Cancer Institute
University of Pisa; University of Roma La Sapienza; University of Turin, Italy; Istituto Oncologico Veneto IRCCS and other collaborators

Recruiting

Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer (Gisel)

Differentiated Thyroid Cancer | Gender

Italy
Glenn J. Hanna
Adenoid Cystic Carcinoma Research Foundation; Cellestia Biotech AG

Recruiting

CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC

Adenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma | Recurrent Adenoid Cystic Carcinoma

United States
National Health Research Institutes, Taiwan
National Cheng-Kung University Hospital

Recruiting

Neoantigen Derived DCs as Cancer Treatment

Solid Tumor | Refractory Tumor

Taiwan
University of California, San Francisco
Merck Sharp & Dohme LLC

Recruiting

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Neuroendocrine Tumors | High Grade Neuroendocrine Carcinoma, Any Site | Well-Differentiated Neuroendocrine Carcinoma

United States
Abramson Cancer Center at Penn Medicine
Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

Renal Cell Carcinoma

United States
Wan-Guang Zhang
The Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaborators

Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma (CCGLC-001)

Hepatocellular Carcinoma Non-resectable

China
Aaron Wolfson

Recruiting

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

Recurrent Endometrial Carcinoma | Unresectable Endometrial Carcinoma

United States
Sun Yat-sen University

Recruiting

TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma

Liver Tumor

China
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Not yet recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)

Mucosal Melanoma

Australia
The First Hospital of Jilin University

Recruiting

Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma (LEADER-001)

Biliary Tract Cancer

China
Universität des Saarlandes

Recruiting

Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC

Head and Neck Squamous Cell Carcinoma

Germany
Fundación GECP

Recruiting

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer (PEERS)

Small Cell Lung Cancer Extensive Stage

Spain
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Intrahepatic Cholangiocarcinoma

China
Merck Sharp & Dohme LLC

Recruiting

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Esophageal Squamous Cell Carcinoma (ESCC)

Japan, Korea, Republic of, Taiwan, Italy, France, Thailand, Turkey, Brazil, Switzerland, Singapore, Germany, Chile, Norway
RenJi Hospital

Not yet recruiting

IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation (iPLENTY-pvtt)

Hepatocellular Carcinoma | Liver Transplant; Complications | Liver Cancer | Portal Vein Thrombosis | Radiotherapy; Complications

China
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Esophageal Squamous Cell Carcinoma

Japan, Korea, Republic of, China, Taiwan, Italy, Switzerland, Brazil, Germany, Singapore, Turkey, Thailand, Chile, Norway
AstraZeneca

Recruiting

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (EMERALD-3)

Hepatocellular Carcinoma

Spain, Korea, Republic of, Canada, Germany, Belgium, United States, France, Italy, Japan, China, Egypt, India, Philippines, Russian Federation, Taiwan, Vietnam, Thailand, Saudi Arabia, Portugal, Brazil, Malaysia, Mexico, Puerto Rico
Elizabeth K. Lee MD
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

Gynecologic Cancer | Ovarian Clear Cell Carcinoma

United States
National Taiwan University Hospital

Not yet recruiting

Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis.

Unresectable Hepatocellular Carcinoma | Pembrolizumab | Stereotactic Body Radiotherapy | Lenvatinib

Taiwan
National University Hospital, Singapore
Eisai Co., Ltd.

Recruiting

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

Breast Cancer

Singapore
Shanghai Chest Hospital
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

NSCLC

China
Merck Sharp & Dohme LLC

Recruiting

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Uterine Cervical Neoplasms | Stomach Neoplasms | Urinary Bladder Neoplasms | Hepatocellular Carcinoma | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Neoplasms

United States, Chile, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, Turkey, Canada
Nanfang Hospital of Southern Medical University

Recruiting

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
GI Innovation, Inc.
Merck Sharp & Dohme LLC

Recruiting

GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Urinary Bladder Cancer | Vulvar Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Vaginal Cancer | Microsatellite Stable...

Korea, Republic of, United States
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Carcinoma, Hepatocellular | Colorectal Neoplasms | Esophageal Neoplasms | Endometrial Neoplasms | Pancreatic Ductal Adenocarcinoma | Biliary Tract Neoplasms

Israel, United States, Australia, Belgium, Chile, France, Korea, Republic of, Netherlands, Spain, New Zealand
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Metastatic Esophageal Squamous Cell Carcinoma

Argentina, Chile, France, United States, Canada, China, Costa Rica, Denmark, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Romania, Ukraine, Singapore, Ma... and more
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Recruiting

Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma

Merkel Cell Carcinoma | Neuroendocrine Carcinoma of the Skin | Trabecular Carcinoma of the Skin

United States
University of Michigan Rogel Cancer Center
Merck Sharp & Dohme LLC; Hoosier Cancer Research Network

Recruiting

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer (PLANE-PC)

Neuroendocrine Tumors | Prostate Cancer Metastatic

United States
Massachusetts General Hospital
Merck Sharp & Dohme LLC; Eisai Inc.

Not yet recruiting

Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement

Human Papilloma Virus | Recurrent Respiratory Papillomatosis

United States
Peking University Cancer Hospital & Institute

Not yet recruiting

Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma

Mucosal Melanoma | Neoadjuvant Treatment

China
Shanghai Jiahui International Hospital
Shanghai Zhongshan Hospital

Recruiting

Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

Advanced Biliary Tract Carcinoma

China
Sheba Medical Center

Recruiting

Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

Urogenital Neoplasms | Neoplasms, Glandular and Epithelial | Genital Neoplasms, Female | Ovarian Diseases | Ovarian Neoplasms | Carcinoma, Ovarian Epithelial | Neoplasm of Stomach | Ovarian Epithelial Tumor

Israel
RenJi Hospital

Recruiting

Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) (Dulect2020-1)

Liver Transplant; Complications | Liver Carcinoma

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC

Hepatocellular Carcinoma

China
RenJi Hospital

Recruiting

Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver Transplant (PLENTY202001)

Liver Transplant; Complications | Hepatocellular Carcinoma Recurrent

China
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Squamous Cell Carcinoma of Head and Neck

United States, Australia, Canada, Denmark, France, Israel, Korea, Republic of, Portugal, Romania, Spain, Taiwan, United Kingdom, Colombia, Brazil, Norway
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Kidney Cancer | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Massachusetts Eye and Ear Infirmary
Eisai Inc.

Recruiting

Lenvatinib in Locally Advanced Invasive Thyroid Cancer

Advanced Cancer | Differentiated Thyroid Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Melanoma

Spain, Poland, United States, Australia, France, Israel, Italy, South Africa, Switzerland, Chile, Greece, Colombia, Hungary
Eisai Inc.

Recruiting

A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor

Neoplasms | Carcinoma, Hepatocellular | Liver Neoplasms | Colorectal Neoplasms | Endometrial Neoplasms

United States, Taiwan, France, Japan, Korea, Republic of

Search clinical trials for: Lenvima

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations